GlassScriptPhysician profile
Yagneshvari S Patel
NPI 1164695904
$5,559.70
in general payments reported to CMS, 2019-2025
23 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $355 · 2021: $543 · 2022: $584 · 2023: $1,144 · 2024: $1,005 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,714.57 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $1,557.26 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Insmed, INC. | $522.30 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $300.68 | 2019-2025 | Zerbaxa, Prevymis, Recarbrio |
| Abbvie INC. | $253.87 | 2021-2025 | |
| Janssen Biotech, INC. | $216.19 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $186.52 | 2019-2024 | Cresemba |
| Shionogi INC | $167.35 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $159.52 | 2021-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $91.25 | 2019-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $82.28 | 2019-2023 | Rezzayo, Orbactiv, Kimyrsa |
| La Jolla Pharmaceutical Company | $40.27 | 2024-2025 | Xacduro, Xerava |
| Takeda Pharmaceuticals U.S.A., INC. | $36.98 | 2024 | Livtencity |
| Napo Pharmaceuticals INC | $34.92 | 2019 | |
| Pfizer INC. | $30.21 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.54 | 2019 | |
| Aimmune Therapeutics, INC. | $25.70 | 2025 | Vowst |
| Electromed, INC. | $24.84 | 2025 | Smartvest |
| Tersera Therapeutics LLC | $21.31 | 2022 | |
| Shire North American Group INC | $21.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.41 | 2025 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $14.53 | 2021 | |
| Redhill Biopharma INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yagneshvari Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.